{
    "clinical_study": {
        "@rank": "30271", 
        "arm_group": {
            "arm_group_label": "Increasing Levels of Lactulose", 
            "arm_group_type": "Experimental", 
            "description": "3 cohorts of 12 patients."
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the efficacy and safety of bisacodyl combined with\n      escalating doses of lactulose to be used as a  preparation for colonoscopy."
        }, 
        "brief_title": "Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Colonoscopy Preparation", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients requiring bowel evacuation for colonoscopy.\n\n        Exclusion Criteria:\n\n          -  Patients with galactosemia (galactose-sensitive diet).\n\n          -  Patients known to be hypersensitive to any of the components of lactulose for oral\n             solution.\n\n          -  Patients with a known abnormality on screening or a vital sign assessments that, in\n             the Investigator's judgment, may pose a significant risk including those pertaining\n             to dehydration or electrolyte shifts.\n\n          -  Patients with a history of impaired renal function.\n\n          -  Patients with current or recent history of hypotension, as defined by the\n             Investigator.\n\n          -  Patients with a history of long Q-T syndrome.\n\n          -  Patients with a history of a failed bowel preparation.\n\n          -  Patients with severe constipation, defined as those patients taking daily\n             prescription or over-the-counter laxatives.\n\n          -  Patients with possible bowel obstruction, gastric retention, bowel perforation, toxic\n             colitis, toxic megacolon, ileus or previous colonic surgery (except hemorrhoidectomy\n             and polypectomy).\n\n          -  Patients on lactulose therapy or receiving any treatment for chronic constipation.\n\n          -  Be pregnant or nursing.\n\n          -  Patients expected to require electrocautery or argon plasma coagulation.\n\n          -  Patients less than 18 years of age.\n\n          -  Inability to understand the requirements of the study or be unwilling to provide\n             written informed consent (as evidenced by signature on an informed consent document\n             approved by an Institutional Review Board [IRB]) and agree to abide by the study\n             restrictions.\n\n          -  Be otherwise unsuitable for the study, in the opinion of the Investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02123017", 
            "org_study_id": "CPI-KR-005"
        }, 
        "intervention": {
            "arm_group_label": "Increasing Levels of Lactulose", 
            "description": "3 cohorts of up to 12 patients, each receiving 15 mg of bisacodyl and 108 ounces of water.  Additionally, the first cohort will  take 90 grams of lactulose and subsequent cohorts will consume 135 or 180 grams according to the dose escalating protocol.", 
            "intervention_name": "Bisacodyl and Lactulose", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Bisacodyl", 
                "Lactulose"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Bowel Evacuation", 
            "Colonoscopy Preparation"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chattanooga", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37421"
                }, 
                "name": "ClinSearch, LLC"
            }, 
            "investigator": {
                "last_name": "Richard Krause, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Observer-blinded, Dose-finding Study to Investigate the Safety, Efficacy, and Patient Preference of Lactulose for Oral Solution With Bisacodyl for Cleansing of the Colon as a Preparation for Colonoscopy in Adults", 
        "overall_contact": {
            "email": "arock@cumberlandpharma.com", 
            "last_name": "Amy Rock, PhD", 
            "phone": "615.255.0068"
        }, 
        "overall_official": {
            "affiliation": "ClinSearch, LLC", 
            "last_name": "Richard Krause, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Efficacy assessed by the physician's determination of the cleanliness of the colon using the Boston Bowel Preparation Scale (BBPS).", 
            "measure": "Efficacy of bisacodyl and lactulose as a preparation for colonoscopy.", 
            "safety_issue": "No", 
            "time_frame": "10-14 hours post last consumption"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02123017"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Safety determined by the incidence and severity of treatment emergent adverse events.", 
                "measure": "Safety of bisacodyl and lactulose as a bowel evacuant", 
                "safety_issue": "Yes", 
                "time_frame": "1 day post last consumption"
            }, 
            {
                "description": "Tolerability assessed by a patient questionnaire.", 
                "measure": "Tolerability of and preference for bisacodyl and lactulose as a bowel evacuant", 
                "safety_issue": "No", 
                "time_frame": "1 day post last consumption"
            }
        ], 
        "source": "Cumberland Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cumberland Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}